Your browser doesn't support javascript.
loading
Non-Labeled, Stable Labeled, or Radiolabelled Approaches for Provision of Intravenous Pharmacokinetics in Humans: A Discussion Piece.
Young, Graeme C; Spracklin, Douglas K; James, Alexander D; Hvenegaard, Mette G; Pedersen, Mette L; Wagner, David S; Georgi, Katrin; Schieferstein, Hanno; Bjornsdottir, Inga; Romeo, Andrea A; Cassidy, Kenneth C; Da-Violante, Georges; Blech, Stefan; Schulz, Simone I; Cuyckens, Filip; Nguyen, Mai Anh; Scarfe, Graeme.
Afiliación
  • Young GC; GSK Research &Development Ltd., Stevenage, UK.
  • Spracklin DK; Pfizer Inc., Groton, Connecticut, USA.
  • James AD; Novartis, Basel, Switzerland.
  • Hvenegaard MG; H. Lundbeck A/S, Copenhagen, Denmark.
  • Pedersen ML; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Wagner DS; AbbVie, North Chicago, Illinois, USA.
  • Georgi K; The Healthcare Business of Merck KGaA, Darmstadt, Germany.
  • Schieferstein H; The Healthcare Business of Merck KGaA, Darmstadt, Germany.
  • Bjornsdottir I; Novo Nordisk, Maaloev, Denmark.
  • Romeo AA; Roche Pharma Research and Early Development, Basel, Switzerland.
  • Cassidy KC; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Da-Violante G; Technologie Servier, Orleans, France.
  • Blech S; Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
  • Schulz SI; Bayer AG, Wuppertal, Germany.
  • Cuyckens F; Janssen R&D, Beerse, Belgium.
  • Nguyen MA; Sanofi, R&D, Frankfurt, Germany.
  • Scarfe G; Sosei Heptares, Great Abington, Cambridge, UK.
Clin Pharmacol Ther ; 115(5): 931-938, 2024 May.
Article en En | MEDLINE | ID: mdl-38018358
ABSTRACT
A review of the use of microdoses and isotopic microtracers for clinical intravenous pharmacokinetic (i.v. PK) data provision is presented. The extent of application of the varied approaches available and the relative merits of each are highlighted with the aim of assisting practitioners in making informed decisions on the most scientifically appropriate design to adopt for any given new drug in development. It is envisaged that significant efficiencies will be realized as i.v. PK data in humans becomes more routinely available for suitable assets in early development, than has been the case prior to the last decade.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Farmacocinética / Toma de Decisiones Límite: Humans Idioma: En Revista: Clin Pharmacol Ther Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Farmacocinética / Toma de Decisiones Límite: Humans Idioma: En Revista: Clin Pharmacol Ther Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido
...